Following on from the release of a steady Q3 financials report, GCAC's innovative data technologies specifically designed for the medical cannabis industry were recognised this week for exceptional performance based on innovation, growth, management or societal impact.

Having previously featured in the Top 100 Market Research Startups and Companies in Canada as well as in the Top 27 Market Research Startups and Companies in Vancouver, GCAC are showing a very defined upward trend. This will be a welcome reward for both the company and investors, finally gaining the recognition earned through the hard work put in over the previous few years.

Brad Moore, the company's CEO, echoed these sentiments by saying:

“Our team is working tirelessly to get our technology in the hands of cultivators and industry professionals and to share our story with medical cannabis consumers who benefit from our innovative ‘one gram grown, one gram consumed’ efficacy measurement.”

The Company is on a roll, announcing plans to operate as a non-possession medical cannabis retailer that connects buyers to cultivators upon approval from Health Canada using a retail dropship model; announcing DeFi funding for Canadian cultivators that license Efixii cannabis blockchain software; and, joining the Canadian Chamber of Commerce’s National Cannabis Working Group and the International Cannabis Council. The company was also recently up-listed to the OTCQB exchange, making shares more broadly available to US investors.